grant
Coagulation Factor XII Recruitment and Activation During Thrombus Formation
Organization BETH ISRAEL DEACONESS MEDICAL CENTERLocation BOSTON, UNITED STATESPosted 1 Sept 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025Activated Blood Coagulation Factor XIIActivated Factor XIIActive Follow-upAffinityAnticoagulationAntithrombotic AgentsAntithrombotic DrugsArg-Gly-AspArginine-Glycine-Aspartic Acid Cell Adhesion DomainAssayBindingBinding SitesBioassayBiological AssayBleedingBlood Coagulation DisordersBlood Coagulation FactorXIBlood PlasmaBlood PlateletsBlood-coagulation factor XIICell Communication and SignalingCell LineCell SignalingCellLineClinicalClottingCo(beta)-cyano-7''-(2-methyl)adeninylcobamideCo-ImmunoprecipitationsCoagulationCoagulation DisorderCoagulation Factor XIICoagulation Factor XIIaCoagulation ProcessCoagulopathyCombining SiteCompetitive BindingComplexCryo-electron MicroscopyCryoelectron MicroscopyDataDeuteriumDevelopmentDiathesisDisease susceptibilityDrug TargetingElectron CryomicroscopyElectron MicroscopyEnzyme PrecursorsEventExhibitsF12 deficiencyFXII deficiencyFactor XIIFactor XII DeficiencyFactor XIIaFibrinolytic AgentsFibrinolytic DrugsFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFollow-Up StudiesFollowup StudiesGenerationsH elementH2 isotopeHageman FactorHageman Factor DeficiencyHageman TraitHemorrhageHemostasisHemostatic functionHumanHydrogenIn VitroIntegrin BindingIntegrinsIntegrins Extracellular MatrixInterferometryIntracellular Communication and SignalingInvestigatorsKO miceKnock-out MiceKnockout MiceKringle DomainsKringlesLigandsMapsMarrow plateletMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMediatingMembrane Protein GeneMembrane ProteinsMembrane-Associated ProteinsModern ManMolecularMolecular ConfigurationMolecular ConformationMolecular InteractionMolecular StereochemistryNegative StainingNull MousePathway interactionsPatientsPhasePhysiologicPhysiologicalPlasmaPlasma SerumPlateletsPlayPre-Clinical ModelPreclinical ModelsPrekallikrein ActivatorProcessProenzymesPropertyProteomicsRGD (sequence)RGD Cell Adhesion DomainRGD DomainRGD MotifRGD Tripeptide SequenceRGD peptideRGD tripeptideReactive SiteReagentReceptor ProteinRecombinant ProteinsRecombinantsReproducibilityResearch PersonnelResearchersReticuloendothelial System, Serum, PlasmaRiskRoleSignal TransductionSignal Transduction SystemsSignalingSiteSolidStrains Cell LinesSurfaceSurface ProteinsTherapeuticThrombocytesThrombolytic AgentsThrombolytic DrugsThrombosisThrombusTreatment EfficacyWorkZymogensactive followupantithrombotic medicationantithromboticsarginyl-glycyl-aspartic acidbiological signal transductionbleeding disorderblood lossclotting disordercompetitively boundconformationconformationalconformational stateconformationallyconformationscryo-EMcryoEMcryogenic electron microscopycultured cell linedevelopmentalexperimentexperimental researchexperimental studyexperimentsfactor Aflow cytophotometryfollow upfollow-upfollowed upfollowupin vivoinhibitorinjury to the vasculatureinsightintegrin boundinterestintervention efficacyliability to diseasemicroscope imagingmicroscopic imagingmicroscopy imagingmouse modelmurine modelnew approachesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel approachesnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeuticsnovel therapyparticlepathwaypreventpreventingreceptorreconstitutereconstitutionrecruitsocial rolestemtargeted agenttherapeutic efficacytherapeutic targettherapy efficacythromboticthrombotic diseasethrombotic disordervascular injury
Description preview
PROJECT SUMMARY
An antithrombotic medication not associated with increased hemorrhage would be a transformative advance in
the treatment of coagulation disorders. Inhibiting coagulation factor XII (FXII) has emerged as a therapeutic
strategy that could “decouple” hemostasis from thrombosis to achieve antithrombotic efficacy without bleeding…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click